In order to help doctors systematically learn and apply immunotherapy, understand the frontier and progress of immunotherapy, deal with adverse reactions of immunotherapy, and gradually realize standardization, specialization, standardization, refinement and informationization, and ultimately benefit the majority of patients. On April 13, 2022, Chengdu High-tech Medical Association held the "Immunotherapy Lecture 3 - 2022 "CAR" Voice CAR-T Clinical Practice Inter-academic Exchange Meeting" online. The meeting invited well-known experts in related fields Give lectures on immunotherapy and other related content, and share the latest research progress.

The meeting was opened and summarized by Professor Zou Liqun and Jia Yongqian from West China Hospital of Sichuan University and Professor Huang Liang from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology. Prof. Tu Sanfang from Zhujiang Hospital of Southern Medical University focused on the interpretation of "CART Treatment of Primary Central DLBCL"; Prof. Yang Yang from Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology focused on sharing "Autologous Transplantation Sequential CD19CAR-T Therapy for Refractory Partners" Sharing and Discussion of Central Invasion of DLBCL Cases"; Professor Liu Yang from PLA General Hospital explained "Clinical Management Pathway of CAR-T Cell Therapy for NHL Toxic and Side Effects"; at the end of the meeting, all the professors launched a stimulating discussion.

This conference provides a platform for clinical medical practitioners and scientific researchers to exchange diagnosis and treatment technologies and academic scientific research results, which is conducive to academic discussions and exchanges of classic cases and cutting-edge technologies in immunotherapy, and establishes a comprehensive and standardized immunotherapy medical treatment platform. idea. It is of great significance to promote high-quality clinical research in the field of medical oncology and promote the level of clinical scientific research.